Research progress in the mechanism of BRAF inhibitor resistance in melanoma / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
;
(12): 576-583, 2020.
Artigo
em Chinês
| WPRIM
| ID: wpr-855841
ABSTRACT
Melanoma is a malignant tumor of melanocyte origin, and BRAF mutations occur in about 50% of melanoma patients clinically. BRAF inhibitors can target mutated BRAF sites, thus rapidly inhibiting the proliferation and promoting apoptosis of tumor cells. However, the subsequent rapid occurrence of drug resistance events seriously restricted the continuous use of such drugs, so it is of great importance to explore the mechanism of BRAF inhibitors resistance. This paper introduces the research progress of BRAF inhibitor resistance in melanoma in recent years, in order to provide some references for the follow-up research and clinical application.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Clinical Pharmacology and Therapeutics
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS